Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.
Biomark Med. 2012 Oct;6(5):613-25. doi: 10.2217/bmm.12.70.
Ovarian cancer is the most lethal gynecological malignancy and survival of this disease has remained relatively unchanged over the past 30 years. A contributing factor to this has been the lack of reliable biomarkers for the clinical management of ovarian cancer. Rapid advances in high-throughput technologies over the past decade has allowed for new and exciting opportunities for biomarker discovery in the field of ovarian cancer, especially with respect to serum biomarkers that can be used for various clinical applications. This review highlights the major genomic and proteomic studies dedicated to ovarian cancer biomarker discovery over the past decade. An emphasis will be placed on the HE4, Risk of Malignancy Algorithm (ROMA) and OVA1™ serum-based tests/algorithms that have recently been approved by the US FDA as ovarian cancer biomarkers.
卵巢癌是最致命的妇科恶性肿瘤，在过去的 30 年中，这种疾病的存活率相对没有变化。造成这种情况的一个因素是缺乏可靠的生物标志物来进行卵巢癌的临床管理。过去十年中高通量技术的快速发展为卵巢癌领域的生物标志物发现带来了新的令人兴奋的机会，特别是在可用于各种临床应用的血清生物标志物方面。这篇综述重点介绍了过去十年中致力于卵巢癌生物标志物发现的主要基因组和蛋白质组研究。将重点介绍最近被美国 FDA 批准为卵巢癌生物标志物的 HE4、恶性肿瘤风险算法 (ROMA) 和 OVA1™基于血清的测试/算法。
